Immunotherapy improves overall survival of the most aggressive breast cancer

Immunotherapy improves overall survival of the most aggressive breast cancer

A study led by the IBCC in Barcelona points to a 27% improvement when adding pembrolizumab to chemotherapy An international study has shown that the addition of a type of immunotherapy, pembrolizumab, to first-line chemotherapy improves the overall survival of patients with advanced triple-negative breast cancer with PD-L1 expression by 27%. This is the KEYNOTE-355 …

Immunotherapy improves overall survival of the most aggressive breast cancer Read More »